Completed PHASE1 INTERVENTIONAL 4-arm NCT01121198

A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects

ASP1941 Phase I Study -Placebo-controlled, Single-dose and Repeated-dose Oral Administration Study in Healthy Adult Male Subjects-

Sponsor: Astellas Pharma Inc

Conditions Healthy Volunteer Pharmacokinetics of ASP1941

Interventions ASP1941 placebo

Updated 6 times since 2017 Last updated: May 10, 2010 Started: Dec 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01121198, this PHASE1 trial focuses on Healthy Volunteer and Pharmacokinetics of ASP1941 and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Sep 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kantou, Japan